Pegaptanib sodium for the treatment of age-related macular degeneration
- 28 January 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (3), 499-508
- https://doi.org/10.1517/14656566.9.3.499
Abstract
(2008). Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opinion on Pharmacotherapy: Vol. 9, No. 3, pp. 499-508. doi: 10.1517/14656566.9.3.499Keywords
This publication has 68 references indexed in Scilit:
- Computer-Based Test to Measure Optimal Visual Acuity in Age-Related Macular DegenerationInvestigative Opthalmology & Visual Science, 2007
- Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic InjuryThe American Journal of Pathology, 2007
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Pegaptanib 1-Year Systemic Safety Results from a Safety–Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular DegenerationOphthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Inhibitors of Ocular NeovascularizationJAMA, 2005
- Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular DegenerationDrugs & Aging, 2004
- Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal DetachmentThe American Journal of Pathology, 2002
- Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor by Human Retinal Pigment Epithelial CellsBiochemical and Biophysical Research Communications, 1993
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990